Abstract
Pseudomonas aeruginosa is a common biofilm-forming bacterial pathogen implicated in diseases of the lungs. The extracellular polymeric substances (EPS) of respiratory Pseudomonas biofilms are largely comprised of anionic molecules such as rhamnolipids and alginate that promote a mucoid phenotype. In this Letter, we examine the ability of negatively-charged fluoroquinolones to transverse the EPS and inhibit the growth of mucoid P. aeruginosa. Anionic fluoroquinolones were further compared with standard antibiotics via a novel microdiffusion assay to evaluate drug penetration through pseudomonal alginate and respiratory mucus from a patient with cystic fibrosis.
| Original language | English |
|---|---|
| Pages (from-to) | 1305-1309 |
| Number of pages | 5 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 15 2016 |
Bibliographical note
Funding Information:This research was supported in part by the Marshall University School of Pharmacy FRS Grant Program and the Office of Experiential Learning for financial support. Special thanks is also given to NASA West Virginia EPSCoR grant program, the National Center for Research Resources, the National Center for Advancing Translational Sciences, and National Institutes of Health (NIH), through Grant UL1TR000117. HDY is supported by NIH P20GM103434 to the West Virginia IDeA Network for Biomedical Research Excellence, and is the co-founder of Progenesis Technologies, LLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
© 2016 Elsevier Ltd. All rights reserved.
Keywords
- Antibacterial
- Biofilm
- Fluoroquinolone
- Mucoid
- Pseudomonas
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Molecular Biology
- Pharmaceutical Science
- Drug Discovery
- Clinical Biochemistry
- Organic Chemistry